Stella’s offer extends beyond a virtual appointment: after the first visit, patients gain access to an app with coaching, symptom tracking and educational material. That can make the service feel continuous, but the clinical encounter and the activities between visits should not be treated as interchangeable. A question about a prescription may need a different recipient from a question about using a tool.
This review examines Stella’s US service and FAQ as available on September 28, 2026. We did not attend an appointment or use the patient app. The focus is how a reader can understand the stated roles, charges and follow-up boundaries before deciding whether the service fits the conversation they need.
The first visit remains a clinical assessment
The Stella FAQ describes an online assessment and virtual visit, with treatment depending on symptoms, history and preferences. It says the service is designed for women aged thirty-five to seventy. That description is not a guarantee of individual eligibility, and it does not establish that everyone in that age range should receive hormone treatment.
Our later-start discussion guide is useful when the history includes a long interval since menopause or an earlier treatment decision. The Winona review provides a contrast with a narrower published HRT age range and written intake. Those are access differences, not evidence that one service’s policy determines the medically correct answer.
Let a symptom record serve the question
The FAQ lists symptom tracking and habit-building tools among the app features unlocked after the first visit. Their availability does not prove that a clinician watches every entry or that an app change triggers an appointment. The reviewed material does not specify a clinical alert pathway for each item a patient records.
Our sleep and hot-flash goals guide can help keep the record purposeful: what changed, how it affects daily life and what the reader wants to understand. A detailed chart can still leave the central question unanswered. Before relying on the app for communication, ask how information reaches the person responsible for the treatment decision.
Coaching and prescribing need distinct responsibilities
Stella’s FAQ describes certified wellness coaching, sleep audio and educational resources alongside specialist visits and referral coordination. It does not present an app exercise as a replacement for medical assessment. We have not evaluated the coaching content, the clinical credentials of an individual user’s team or how a concern moves between those parts of the service.
A comparison with Gennev’s physician and dietitian appointments is useful because both models involve more than one type of support. Before a follow-up, clarify who can answer the unresolved question. The availability of several professionals or resources does not by itself establish that they share notes or take responsibility for the same clinical decisions.
The average copay is not an individual quotation
The FAQ reports a $45 average copay and offers an estimate after account creation and collection of policy details. An average is not a ceiling or a verified bill. For people outside its insurance network, the published charges are $200 for the initial visit and $90 for each follow-up.
Stella says it can provide a superbill for possible reimbursement; that does not guarantee an insurer will pay. Prescription costs are separate and depend on the plan and pharmacy. The service page advertises broad access, but a reader still needs confirmation of the clinician, state, appointment and financial arrangement that apply to their own booking.
Declining medication can still be part of the visit
Stella explicitly says people who do not want medication can discuss other approaches in its FAQ. It also lists both hormonal and nonhormonal prescribing. A reader can therefore state a preference or concern without assuming that buying a hormone product is the purpose of every appointment.
That openness should not be mistaken for proof that any advertised approach will relieve a particular problem. FDA guidance describes treatment benefits and risks without promising universal suitability. The meaningful conversation is about the concern, the available assessment and the reasons for a proposed option, including what remains uncertain and whether a different care setting is needed.
Discuss intimate or new symptoms explicitly
Stella’s care page includes vaginal concerns among its menopause services. Our vaginal-symptom guide helps make that part of the agenda rather than expecting a clinician to infer it from a general wellness goal. Describing a concern is not the same as assigning it to menopause or choosing its treatment.
The bleeding-history preparation guide concerns another subject that may need separate attention. A broad app label or symptom category cannot establish the cause of bleeding. This review does not supply a triage process; it emphasizes that a new clinical concern needs an appropriate professional response, not merely another tracking entry or coaching activity.
Establish what ongoing support actually means
The FAQ promises care coordination and referral support, but the reviewed pages do not set out a universal follow-up interval, complete cancellation schedule or guaranteed response time for every clinical message. Those are relevant questions before treating ongoing support as a fully specified service. A reader can ask which encounters are separately charged and how referrals are followed through.
Stella’s combination of a clinic and an app is a recognizable care model, not evidence that every part substitutes for another. The appointment should leave the person clear about the plan and the next contact. We cannot verify that outcome from the public offer or infer it from the service’s testimonials and improvement language.
Read alongside the article
Sources & notes.
These sources provide provider descriptions or medical context. They do not replace an individual clinical assessment.
- Stella US: visits, prescriptions and insurance FAQ ↗US provider FAQ; average copay and self-pay visit charges distinct from pharmacy costs · Checked 2026-09-28
- Stella US: virtual menopause clinic ↗US provider service page only; no UK prices or delivery terms transferred · Checked 2026-09-28
- FDA: Menopause ↗Current federal patient guidance; individualized benefits/risks and prevention limits, no class-wide labeling-change inference · Checked 2026-09-28